What is this publication about?

In this publication, researchers produced the most geographically comprehensive individual-patient data meta-analysis to date, examining the role of malaria parasite mutations in the growing antimalarial drug resistance. Specifically, this work illustrated the association between mutations in the Plasmodium falciparum Kelch13 gene and a delayed response to artemisinin-based malaria treatment, the current mainstay for this type of malaria.

The study investigated data from 16,823 patients across 45 studies, 539 study sites and 33 countries, including 22 countries in Africa.

Why is this important?

The findings are particularly important in Africa, where artemisinin partial resistance is now emerging independently in several parasite populations.

This publication is special for its coverage and inclusivity, as it is the first study of its kind to include the most recent, African-specific data to this extent. By bringing together data from thousands of patients across diverse transmission settings, researchers were able to better understand how resistance is emerging across the continent and, importantly, how they can improve its detection.

How can this make a difference?

The findings are key to keeping national malaria control programs in Africa and international organisations armed with the latest information when making decisions about malaria treatment guidelines and how we consider delayed clearance after treatment or early treatment failure.

In September 2026, Dr Stephanie van Wyk and Dr Prabin Dahal presented the findings to the World Health Organisation Working Group on artemisinin partial resistance thresholds. This contributed to discussions with the World Health Organisation and took an important step toward translating this collaborative research into stronger surveillance and public health action.